Novel end points for clinical trials in young children with cystic fibrosis
Access Status
Authors
Date
2013Type
Metadata
Show full item recordCitation
Source Title
ISSN
School
Collection
Abstract
Cystic fibrosis (CF) lung disease commences early in the disease progression and is the most common cause of mortality. While new CF disease-modifying agents are currently undergoing clinical trial evaluation, the implementation of such trials in young children is limited by the lack of age-appropriate clinical trial end points. Advances in infant and preschool lung function testing, imaging of the chest and the development of biochemical biomarkers have led to increased possibility of quantifying mild lung disease in young children with CF and objectively monitoring disease progression over the course of an intervention. Despite this, further standardization and development of these techniques is required to provide robust objective measures for clinical trials in this age group.
Related items
Showing items related by title, author, creator and subject.
-
Chang, Sungwon (2012)Globally individuals and health care systems are facing the burden of chronic illness. The impact of the increasing burden of non-communicable diseases is experienced by individuals and health care systems. Across the ...
-
Ramelet, Anne-Sylvie; Fonjallaz, B.; Rapin, J.; Gueniat, C.; Hofer, M. (2014)Background: Pediatric rheumatic diseases have a significant impact on children's quality of life and family functioning. Disease control and management of the symptoms are important to minimize disability and pain. ...
-
Martin, M.; Holmes, F.; Ejlertsen, B.; Delaloge, S.; Moy, B.; Iwata, H.; von Minckwitz, G.; Chia, S.; Mansi, J.; Barrios, C.; Gnant, M.; Tomaševic, Z.; Denduluri, N.; Šeparovic, R.; Gokmen, E.; Bashford, A.; Ruiz Borrego, M.; Kim, S.; Jakobsen, E.; Ciceniene, A.; Inoue, K.; Overkamp, F.; Heijns, J.; Armstrong, A.; Link, J.; Joy, A.; Bryce, R.; Wong, A.; Moran, S.; Yao, B.; Xu, F.; Auerbach, A.; Buyse, M.; Chan, Arlene; ExteNET Study Group (2017)Background: ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with ...